Open AccessEarly Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C
Author(s) -
Louis W. C. Liu,
George Tomlinson,
Tony Mazzulli,
Alison D. Murray,
Jenny Heathcote
Publication year - 2003
Publication title -
canadian journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 1916-7237
pISSN - 0835-7900
DOI - 10.1155/2003/351816
Subject(s) - ribavirin , medicine , viral load , chronic hepatitis , hepatitis c virus , interferon , alpha interferon , gastroenterology , hepatitis c , immunology , virus
Treatment of chronic hepatitis C virus (HCV) infection with interferon alpha-2b and ribavirin is costly in terms of side effects, medical resources and drug costs. Furthermore, less than 50% of patients overall have a sustained virological response (SVR).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom